GlaxoSmithKline plc (GSK)


NYSE - NYSE Real Time Price. Currency in USD
43.62+0.08 (+0.17%)
As of 2:18 PM EDT. Market open.
People also watch:
AZNNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open43.54
Prev Close43.55
Bid43.63 x 1400
Ask43.64 x 2000
Day's Range43.39 - 43.70
52wk Range37.24 - 45.58
1y Target EstN/A
Market Cap106.03B
P/E Ratio (ttm)2,726.56
Beta1.00
Volume1,467,663
Avg Vol (3m)3,390,698
Dividend & Yield2.20 (5.06%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com44 minutes ago

    Gilead Sciences: Don't Expect Perfection

    As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.

  • Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)
    Insider Monkey2 hours ago

    Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)

    Introduction Back on May 12, 2015, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee released a briefing document detailing the process for licensure of Ebola vaccines and the required demonstration of effectiveness. This Market Exclusive Inside the FDA report aims to go inside this briefing document, break it down, and […]

  • Better Buy: GlaxoSmithKline plc vs. AbbVie
    Motley Fool5 hours ago

    Better Buy: GlaxoSmithKline plc vs. AbbVie

    Which is the better large-cap drug stock to buy right now?